Magenta’s stem cell therapy MGTA-456 met efficacy targets in the first few patients enrolled in a phase 2 trial to be presented at ASH next month, but with a question about safety.
Fresh off of striking a?research deal?with Ladenburg, Germany-based?Heidelberg Pharma GmbH,?Magenta Therapeutics?secured $52 million in Series C financing.